Physical activity and natural Anti-VIP antibodies: Potential role in breast and prostate cancer therapy

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Veljkovic, Milena ^a   Dopsaj, Violeta ^b   Dopsaj, Milivoj ^c   Branch, Donald R ^d   Veljkovic, Nevena ^e   Sakarellos Daitsiotis, Maria M ^f   Veljkovic, Veljko ^e   Glisic, Sanja ^e   Colombatti, Alfonso ^g  

^a Sveti Sava Hospital   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d CANADIAN BLOOD SERVICES   (Canada)

^e UNIVERSITY OF BELGRADE   (Serbia)

^f UNIVERSITY OF IOANNINA   (Greece)

^g CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; PEPTIDE ANTIBODY; VASOACTIVE INTESTINAL POLYPEPTIDE ANTIBODY;

ADULT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; ATHLETE; BREAST CANCER; CANCER CONTROL; CANCER INHIBITION; CANCER PATIENT; CANCER THERAPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; EXERCISE INTENSITY; FEMALE; HUMAN; IMMUNOREACTIVITY; IMMUNOSTIMULATION; MALE; PHYSICAL ACTIVITY; PROSTATE CANCER; STRUCTURE ANALYSIS;

ADULT; AGED; ANTIBODIES; ATHLETES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; PEPTIDES; PROSTATIC NEOPLASMS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 82355183892     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028304     Document Type: Article

References (60)

1. Gespach C, Bawab W, Chastre E, Emami S, Yanaihara N, et al. (1988) Pharmacology and molecular identification of vasoactive intestinal peptide (VIP) receptors in normal and cancerous gastric mucosa in man. Biochemical and biophysical research communications 151: 939-947.
2. Moody TW, Leyton J, Gozes I, Lang L, Eckelman WC, (1998) VIP and breast cancer. Annals of the New York Academy of Sciences 865: 290-296.
3. Madsen B, Georg B, Madsen MW, Fahrenkrug J, (2000) Downregulation of VPAC1R expression in breast cancer cell lines. Annals of the New York Academy of Sciences 921: 33-36.
4. Gespach C, Bawab W, de Cremoux P, Calvo F, (1988) Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells. Cancer research 48: 5079-5083.
5. Dagar S, Sekosan M, Rubinstein I, Onyuksel H, (2001) Detection of VIP receptors in MNU-induced breast cancer in rats: implications for breast cancer targeting. Breast cancer research and treatment 65: 49-54.
6. Garcia-Fernandez MO, Collado B, Bodega G, Cortes J, Ruiz-Villaespesa A, et al. (2005) Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology 20: 327-333.
7. Moody TW, Jensen RT, (2006) Breast cancer VPAC1 receptors. Annals of the New York Academy of Sciences 1070: 436-439.
8. Moody TW, Gozes I, (2007) Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer. Current pharmaceutical design 13: 1099-1104.
9. Moody TW, Hill JM, Jensen RT, (2003) VIP as a trophic factor in the CNS and cancer cells. Peptides 24: 163-177.
10. Valdehita A, Carmena MJ, Collado B, Prieto JC, Bajo AM, (2007) Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells. Regulatory peptides 144: 101-108.
11. Valdehita A, Bajo AM, Fernandez-Martinez AB, Arenas MI, Vacas E, et al. (2010) Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer. Peptides 31: 2035-2045.
12. Valdehita A, Bajo AM, Schally AV, Varga JL, Carmena MJ, et al. (2009) Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells. Molecular and cellular endocrinology 302: 41-48.
13. Valdehita A, Carmena MJ, Bajo AM, Prieto JC, (2011) RNA interference-directed silencing of VPAC(1) receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells. Molecular and cellular endocrinology.
14. Collado B, Gutierrez-Canas I, Rodriguez-Henche N, Prieto JC, Carmena MJ, (2004) Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells. Regulatory peptides 119: 69-75.
15. Collado B, Sanchez-Chapado M, Prieto JC, Carmena MJ, (2006) Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells. Molecular and cellular endocrinology 249: 116-122.
16. Collado B, Carmena MJ, Clemente C, Prieto JC, Bajo AM, (2007) Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model. Peptides 28: 1896-1901.
17. Sotomayor S, Carmena MJ, Schally AV, Varga JL, Sanchez-Chapado M, et al. (2007) Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone. International journal of oncology 31: 1223-1230.
18. Gutierrez-Canas I, Juarranz MG, Collado B, Rodriguez-Henche N, Chiloeches A, et al. (2005) Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K. The Prostate 63: 44-55.
19. Nagakawa O, Junicho A, Akashi T, Koizumi K, Matsuda T, et al. (2005) Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells. Oncology reports 13: 1217-1221.
20. Gkonos PJ, Ashby MH, Andrade AA, (1996) Vasoactive intestinal peptide stimulates prostate-specific antigen secretion by LNCaP prostate cancer cells. Regulatory peptides 65: 153-157.
21. Fernandez-Martinez AB, Bajo AM, Sanchez-Chapado M, Prieto JC, Carmena MJ, (2009) Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells. The Prostate 69: 774-786.
22. Fernandez-Martinez AB, Bajo AM, Isabel Arenas M, Sanchez-Chapado M, Prieto JC, et al. (2010) Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1. Cancer letters 299: 11-21.
23. Rekasi Z, Schally AV, Plonowski A, Czompoly T, Csernus B, et al. (2001) Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide. The Prostate 48: 188-199.
24. Zia H, Hida T, Jakowlew S, Birrer M, Gozes Y, et al. (1996) Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer research 56: 3486-3489.
25. Moody TW, Leyton J, Chan D, Brenneman DC, Fridkin M, et al. (2001) VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. Breast cancer research and treatment 68: 55-64.
26. Moody TW, Dudek J, Zakowicz H, Walters J, Jensen RT, et al. (2004) VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice. Life sciences 74: 1345-1357.
27. Moody TW, Czerwinski G, Tarasova NI, Michejda CJ, (2002) VIP-ellipticine derivatives inhibit the growth of breast cancer cells. Life sciences 71: 1005-1014.
28. Moody TW, Mantey SA, Fuselier JA, Coy DH, Jensen RT, (2007) Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells. Peptides 28: 1883-1890.
29. Plonowski A, Varga JL, Schally AV, Krupa M, Groot K, et al. (2002) Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity. International journal of cancer Journal international du cancer 98: 624-629.
30. Galbo H, Hilsted J, Fahrenkrug J, Schaffalitzky De Muckadell OB, (1979) Fasting and prolonged exercise increase vasoactive intestinal polypeptide (VIP) in plasma. Acta physiologica Scandinavica 105: 374-377.
31. Oktedalen O, Opstad PK, Fahrenkrug J, Fonnum F, (1983) Plasma concentration of vasoactive intestinal polypeptide during prolonged physical exercise, calorie supply deficiency, and sleep deprivation. Scandinavian journal of gastroenterology 18: 1057-1062.
32. Oektedalen O, Opstad PK, Schaffalitzky de Muckadell OB, Fausa O, Flaten O, (1983) Basal hyperchlorhydria and its relation to the plasma concentrations of secretin, vasoactive intestinal polypeptide (VIP) and gastrin during prolonged strain. Regulatory peptides 5: 235-244.
33. Oktedalen O, Opstad PK, Schaffalitzky de Muckadell OB, (1983) The plasma concentrations of secretin and vasoactive intestinal polypeptide (VIP) after long-term, strenuous exercise. European journal of applied physiology and occupational physiology 52: 5-8.
34. Woie L, Kaada B, Opstad PK, (1986) Increase in plasma vasoactive intestinal polypeptide (VIP) in muscular exercise in humans. General pharmacology 17: 321-326.
35. Opstad PK, (1987) The plasma vasoactive intestinal peptide (VIP) response to exercise is increased after prolonged strain, sleep and energy deficiency and extinguished by glucose infusion. Peptides 8: 175-178.
36. MacLaren DP, Raine NM, O'Connor AM, Buchanan KD, (1995) Human gastrin and vasoactive intestinal polypeptide responses to endurance running in relation to training status and fluid ingested. Clinical science 89: 137-143.
37. Paul S, Said SI, (1988) Human autoantibody to vasoactive intestinal peptide: increased incidence in muscular exercise. Life sciences 43: 1079-1084.
38. Veljkovic M, Dopsaj V, Stringer WW, Sakarellos-Daitsiotis M, Zevgiti S, et al. (2010) Aerobic exercise training as a potential source of natural antibodies protective against human immunodeficiency virus-1. Scandinavian journal of medicine & science in sports 20: 469-474.
39. Paul S, Heinz-Erian P, Said SI, (1985) Autoantibody to vasoactive intestinal peptide in human circulation. Biochemical and biophysical research communications 130: 479-485.
40. Paul S, Volle DJ, Beach CM, Johnson DR, Powell MJ, et al. (1989) Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science 244: 1158-1162.
41. Paul S, Volle DJ, Powell MJ, Massey RJ, (1990) Site specificity of a catalytic vasoactive intestinal peptide antibody. An inhibitory vasoactive intestinal peptide subsequence distant from the scissile peptide bond. The Journal of biological chemistry 265: 11910-11913.
42. Mei S, Mody B, Eklund SH, Paul S, (1991) Vasoactive intestinal peptide hydrolysis by antibody light chains. The Journal of biological chemistry 266: 15571-15574.
43. Paul S, Mei S, Mody B, Eklund SH, Beach CM, et al. (1991) Cleavage of vasoactive intestinal peptide at multiple sites by autoantibodies. The Journal of biological chemistry 266: 16128-16134.
44. Veljkovic V, Metlas R, Raspopovic J, Pongor S, (1992) Spectral and sequence similarity between vasoactive intestinal peptide and the second conserved region of human immunodeficiency virus type 1 envelope glycoprotein (gp120): possible consequences on prevention and therapy of AIDS. Biochemical and biophysical research communications 189: 705-710.
45. Velikovic V, Metlas R, Danilo V, Cavor L, Pejinovic N, et al. (1993) Natural autoantibodies cross-react with a peptide derived from the second conserved region of HIV-1 envelope glycoprotein gp120. Biochemical and biophysical research communications 196: 1019-1024.
46. Veljkovic N, Branch DR, Metlas R, Prljic J, Vlahovicek K, et al. (2003) Design of peptide mimetics of HIV-1 gp120 for prevention and therapy of HIV disease. The journal of peptide research: official journal of the American Peptide Society 62: 158-166.
47. Veljkovic V, Veljkovic N, Metlas R, (2004) Molecular makeup of HIV-1 envelope protein. International reviews of immunology 23: 383-411.
48. Djordjevic A, Veljkovic M, Antoni S, Sakarellos-Daitsiotis M, Krikorian D, et al. (2007) The presence of antibodies recognizing a peptide derived from the second conserved region of HIV-1 gp120 correlates with non-progressive HIV infection. Current HIV research 5: 443-448.
49. Friedenreich CM, (2010) Physical Activity and Breast Cancer: Review of the Epidemiologic Evidence and Biologic Mechanisms. 188: 125-139.
50. Frisch RE, Wyshak G, Witschi J, Albright NL, Albright TE, et al. (1987) Lower lifetime occurrence of breast cancer and cancers of the reproductive system among former college athletes. International journal of fertility 32: 217-225.
51. Frisch RE, Wyshak G, Albright NL, Albright TE, Schiff I, et al. (1992) Former athletes have a lower lifetime occurrence of breast cancer and cancers of the reproductive system. Advances in experimental medicine and biology 322: 29-39.
52. Wyshak G, Frisch RE, (2000) Breast cancer among former college athletes compared to non-athletes: a 15-year follow-up. British journal of cancer 82: 726-730.
53. Irwin ML, Smith AW, McTiernan A, Ballard-Barbash R, Cronin K, et al. (2008) Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 26: 3958-3964.
54. McTiernan A, Irwin M, Vongruenigen V, (2010) Weight, physical activity, diet, and prognosis in breast and gynecologic cancers. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 28: 4074-4080.
55. Ibrahim EM, Al-Homaidh A, (2010) Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies. Medical oncology.
56. Torti DC, Matheson GO, (2004) Exercise and prostate cancer. Sports medicine 34: 363-369.
57. Leitzmann MF, (2011) Physical activity and genitourinary cancer prevention. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer 186: 43-71.
58. Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM, (2011) Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 29: 726-732.
59. Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, et al. (2011) Physical Activity after Diagnosis and Risk of Prostate Cancer Progression: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer research.
60. Bompa TO, Carrera M, (2005) Periodization training for sports. Champaign, IL: Human Kinetics. ix, 259.